SEC Form 4 · accession 0001193125-26-316279
Intellia Therapeutics, Inc. · NTLA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Edward J Dulac III
Officer — EVP, Chief Financial Officer
Period of report
Jul 22, 2026
Accepted (ET)
Jul 24, 2026 · 5:26 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001652130
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jul 22, 2026 | S | 8,111 | $11.25 | D | 148,175 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on July 22, 2026, and does not represent a volitional trade by the Reporting Person.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.25 to $11.28, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 22, 2026 at each separate price.